Research ExplorerPublicationsSynergistic effects of erlotinib and everolimus on bronchial...

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.

Standard

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. / Bago-Horvath, Zsuzsanna; Sieghart, Wolfgang; Grusch, Michael; Lackner, Andreas; Hayden, Hubert; Pirker, Christine; Komina, Oxana; Węsierska-Gądek, Józefa; Haitel, Andrea; Filipits, Martin; Berger, Walter; Schmid, Katharina.

In: NEUROENDOCRINOLOGY, Vol. 96, No. 3, 3, 2012, p. 228-237.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bago-Horvath, Z, Sieghart, W, Grusch, M, Lackner, A, Hayden, H, Pirker, C, Komina, O, Węsierska-Gądek, J, Haitel, A, Filipits, M, Berger, W & Schmid, K 2012, 'Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.', NEUROENDOCRINOLOGY, vol. 96, no. 3, 3, pp. 228-237. <http://www.ncbi.nlm.nih.gov/pubmed/22378048?dopt=Citation>

APA

Bago-Horvath, Z., Sieghart, W., Grusch, M., Lackner, A., Hayden, H., Pirker, C., Komina, O., Węsierska-Gądek, J., Haitel, A., Filipits, M., Berger, W., & Schmid, K. (2012). Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. NEUROENDOCRINOLOGY, 96(3), 228-237. [3]. http://www.ncbi.nlm.nih.gov/pubmed/22378048?dopt=Citation

Vancouver

Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C et al. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. NEUROENDOCRINOLOGY. 2012;96(3):228-237. 3.

Bibtex

@article{5fdc8c81e2b547508b3bacb5e087ac4d,
title = "Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.",
abstract = "Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) are crucial targets in cancer therapy. Combined inhibition of both targets yielded synergistic effects in vitro and in vivo in several cancer entities. However, the impact of EGFR and mTOR expression and combined inhibition in neuroendocrine lung tumors other than small-cell lung cancer remains unclear.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Child, Cell Line, Tumor, Protein Kinase Inhibitors/pharmacology, Receptor, Epidermal Growth Factor/metabolism, Antineoplastic Agents/pharmacology, Proto-Oncogene Proteins c-akt/metabolism, Cell Survival/drug effects, TOR Serine-Threonine Kinases/metabolism, Carcinoma, Bronchogenic/*metabolism/pathology, Carcinoma, Neuroendocrine/*metabolism/pathology, Carcinoma, Non-Small-Cell Lung/metabolism/pathology, Lung Neoplasms/metabolism/pathology, Quinazolines/*pharmacology, Signal Transduction/*drug effects, Sirolimus/*analogs & derivatives/pharmacology, Adult, Humans, Male, Aged, Female, Middle Aged, Adolescent, Young Adult, Child, Cell Line, Tumor, Protein Kinase Inhibitors/pharmacology, Receptor, Epidermal Growth Factor/metabolism, Antineoplastic Agents/pharmacology, Proto-Oncogene Proteins c-akt/metabolism, Cell Survival/drug effects, TOR Serine-Threonine Kinases/metabolism, Carcinoma, Bronchogenic/*metabolism/pathology, Carcinoma, Neuroendocrine/*metabolism/pathology, Carcinoma, Non-Small-Cell Lung/metabolism/pathology, Lung Neoplasms/metabolism/pathology, Quinazolines/*pharmacology, Signal Transduction/*drug effects, Sirolimus/*analogs & derivatives/pharmacology",
author = "Zsuzsanna Bago-Horvath and Wolfgang Sieghart and Michael Grusch and Andreas Lackner and Hubert Hayden and Christine Pirker and Oxana Komina and J{\'o}zefa W{\c e}sierska-G{\c a}dek and Andrea Haitel and Martin Filipits and Walter Berger and Katharina Schmid",
year = "2012",
language = "English",
volume = "96",
pages = "228--237",
journal = "NEUROENDOCRINOLOGY",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "3",

}

RIS

TY - JOUR

T1 - Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.

AU - Bago-Horvath, Zsuzsanna

AU - Sieghart, Wolfgang

AU - Grusch, Michael

AU - Lackner, Andreas

AU - Hayden, Hubert

AU - Pirker, Christine

AU - Komina, Oxana

AU - Węsierska-Gądek, Józefa

AU - Haitel, Andrea

AU - Filipits, Martin

AU - Berger, Walter

AU - Schmid, Katharina

PY - 2012

Y1 - 2012

N2 - Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) are crucial targets in cancer therapy. Combined inhibition of both targets yielded synergistic effects in vitro and in vivo in several cancer entities. However, the impact of EGFR and mTOR expression and combined inhibition in neuroendocrine lung tumors other than small-cell lung cancer remains unclear.

AB - Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) are crucial targets in cancer therapy. Combined inhibition of both targets yielded synergistic effects in vitro and in vivo in several cancer entities. However, the impact of EGFR and mTOR expression and combined inhibition in neuroendocrine lung tumors other than small-cell lung cancer remains unclear.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Child

KW - Cell Line, Tumor

KW - Protein Kinase Inhibitors/pharmacology

KW - Receptor, Epidermal Growth Factor/metabolism

KW - Antineoplastic Agents/pharmacology

KW - Proto-Oncogene Proteins c-akt/metabolism

KW - Cell Survival/drug effects

KW - TOR Serine-Threonine Kinases/metabolism

KW - Carcinoma, Bronchogenic/metabolism/pathology

KW - Carcinoma, Neuroendocrine/metabolism/pathology

KW - Carcinoma, Non-Small-Cell Lung/metabolism/pathology

KW - Lung Neoplasms/metabolism/pathology

KW - Quinazolines/pharmacology

KW - Signal Transduction/drug effects

KW - Sirolimus/analogs & derivatives/pharmacology

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Adolescent

KW - Young Adult

KW - Child

KW - Cell Line, Tumor

KW - Protein Kinase Inhibitors/pharmacology

KW - Receptor, Epidermal Growth Factor/metabolism

KW - Antineoplastic Agents/pharmacology

KW - Proto-Oncogene Proteins c-akt/metabolism

KW - Cell Survival/drug effects

KW - TOR Serine-Threonine Kinases/metabolism

KW - Carcinoma, Bronchogenic/metabolism/pathology

KW - Carcinoma, Neuroendocrine/metabolism/pathology

KW - Carcinoma, Non-Small-Cell Lung/metabolism/pathology

KW - Lung Neoplasms/metabolism/pathology

KW - Quinazolines/pharmacology

KW - Signal Transduction/drug effects

KW - Sirolimus/analogs & derivatives/pharmacology

M3 - SCORING: Journal article

VL - 96

SP - 228

EP - 237

JO - NEUROENDOCRINOLOGY

JF - NEUROENDOCRINOLOGY

SN - 0028-3835

IS - 3

M1 - 3

ER -